Displaying 109 - 120 of 122
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Displaying 109 - 120 of 122